Invoke Capital et al. inject $14m into Sophia Genetics

The fresh capital will be used to accelerate the European adoption of the firm's clinical analytics for genetic diseases.

Following the deal, Sophia also gains access to Invoke's portfolio company Genalys, a Cambridge-based big data company in the field of genetic information. Both companies will work together to provide accurate clinical analytics services to hospitals and clinics across Europe.

Invoke will use its experience in cloud data security and scalability to boost Sophia's genetic sequencing data bank.

Previous financing
In April 2013, Sophia raised CHF 2.8m in a series-A funding round. In 2012, the company received seed funding of €653,000.

Company
Founded in March 2011 in the scientific incubator Incubation Park – part of the Ecole Polytechnique Fédérale de Lausanne – Sophia uses algorithms to diagnose genetic diseases. It attempts to provide a clinical approach to data-driven medicine, meaning clinicians and hospitals are supplied with accurate clinical analytics services for early diagnosis and treatment of cancer and genetic diseases.

Sophia provides clinicians with bioinformatics pipelines and visualisation tools for more than 70 commercial panels and proprietary custom panels. It obtains CE-IVD marking for each supported pipeline and ensures it is compliant with European Data Privacy Laws. It is also working on extending its capability to encompass whole exomes and genomes.

Its software-as-a-service offering, dropGen, covers the bioinformatic analysis protocol, the validation and quality control process, the presentation of results of genetic tests to clinicians and the protection of patient DNA sequence data.

Sophia employs 20 people and has recently opened offices in the UK and France.

People
Jurgi Camblong is CEO of Sophia. Mike Lynch is founder of Invoke.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Technology
• Switzerland